Urine and Serum Sex Steroid Profile in Testosterone-treated Transgender and Hypogonadal and Healthy Control Men.
J Clin Endocrinol Metab. 2018 Mar 22;:
Authors: Savkovic S, Lim S, Jayadev V, Conway A, Turner L, Curtis D, Goebel C, Handelsman DJ
Abstract
Background: The impact of testosterone (T) treatment on anti-doping detection tests in transgender (F2M) men is unknown. We investigated urine and serum sex steroid and LH profiles in T-treated transgender (F2M) to determine whether and, if so, how they differed from hypogonadal and healthy control men.
Method: Healthy transgender (n=23) and hypogonadal (n=24) men treated with 1000mg injectable T undecanoate aged 18-50 years provided trough urine and blood samples and an additional earlier post-injection sample (n=21). Healthy control men (n=20) provided a single blood and urine sample. Steroids were measured by MS-based methods in urine and serum, LH by immunoassay and UGT2B17 genotype by polymerase chain reaction (PCR).
Results: Urine LH, hCG, T, epitestosterone (EpiT), androsterone (A), etiocholanolone (Etio), A/Etio ratio, DHEA, DHT, 5α,3α- and 5β, 3α androstenediols did not differ between groups or by time since last testosterone injection. Urine T/EpiT (T/E) ratio was <4 in all controls and 12/68 (18%) samples from T-treated men but there was no difference between testosterone treated groups. Serum estradiol, estrone and DHEA were higher in transgender men and serum T and DHT were higher on earlier compared with trough blood samples but serum LH, FSH, 3α- and 3β 5α diols did not differ between groups.
Conclusion: Urine anti-doping detection tests in T treated transgender men can be interpreted like T treated hypogonadal men and are unaffected by time since last T dose. Serum steroids are more sensitive to detect exogenous T administration early but not later after the last testosterone dose.
PMID: 29584875 [PubMed - as supplied by publisher]
https://ift.tt/2GCO5FW
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου